Sorrento Therapeutics, a publicly-traded, development-stage biopharmaceutical company, and BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev, have entered into an option and license agreement covering several anti-Hepatitis C Virus (HCV) antibody clones identified from patients who have recovered from HCV infections. Sorrento plans to develop these early findings into a potential therapeutic product.

This collaboration utilizes each organization to create a product opportunity consisting of therapeutic and/or prophylactic agents against HCV infections. Sorrento will be responsible for developing the anti-HCV antibody products.